These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 2842677)
1. Protection against Japanese encephalitis by inactivated vaccines. Hoke CH; Nisalak A; Sangawhipa N; Jatanasen S; Laorakapongse T; Innis BL; Kotchasenee S; Gingrich JB; Latendresse J; Fukai K N Engl J Med; 1988 Sep; 319(10):608-14. PubMed ID: 2842677 [TBL] [Abstract][Full Text] [Related]
2. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893 [TBL] [Abstract][Full Text] [Related]
3. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines. Nimmannitya S; Hutamai S; Kalayanarooj S; Rojanasuphot S Southeast Asian J Trop Med Public Health; 1995 Dec; 26(4):689-93. PubMed ID: 9139377 [TBL] [Abstract][Full Text] [Related]
4. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine--results from 30 years experience in Taiwan. Yang SE; Pan MJ; Tseng HF; Liau MY Vaccine; 2006 Mar; 24(14):2669-73. PubMed ID: 16314007 [TBL] [Abstract][Full Text] [Related]
5. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Halstead SB; Thomas SJ Expert Rev Vaccines; 2011 Mar; 10(3):355-64. PubMed ID: 21434803 [TBL] [Abstract][Full Text] [Related]
6. [A large-scale study on the safety and epidemiological efficacy of Japanese encephalitis (JE) live vaccine (SA14-14-2) in the JE endemic areas]. Zhou B; Jia L; Xu X Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Feb; 20(1):38-41. PubMed ID: 10682513 [TBL] [Abstract][Full Text] [Related]
7. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand. Chotpitayasunondh T; Sohn YM; Yoksan S; Min J; Ohrr H J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S195-203. PubMed ID: 22043776 [TBL] [Abstract][Full Text] [Related]
8. Japanese encephalitis vaccines: moving away from the mouse brain. Zanin MP; Webster DE; Martin JL; Wesselingh SL Expert Rev Vaccines; 2003 Jun; 2(3):407-16. PubMed ID: 12903806 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chambonneau L; Saluzzo JF; Bhamarapravati N Pediatr Infect Dis J; 2004 Feb; 23(2):99-109. PubMed ID: 14872173 [TBL] [Abstract][Full Text] [Related]
10. The efficacy of Japanese encephalitis vaccine in Henan, China: a case-control study. Luo D; Yin H; Xili L; Song J; Wang Z Southeast Asian J Trop Med Public Health; 1994 Dec; 25(4):643-6. PubMed ID: 7667706 [TBL] [Abstract][Full Text] [Related]
11. Japanese encephalitis: development of new candidate vaccines. Bharati K; Vrati S Expert Rev Anti Infect Ther; 2006 Apr; 4(2):313-24. PubMed ID: 16597211 [TBL] [Abstract][Full Text] [Related]
12. [Study on the strategy of Japanese encephalitis immunization using live attenuated vaccine combined with inactivated vaccine]. Ma FB; Zheng L; Bi C; Tao H; Zhou YL; Zhang JL; Tang FY; Xie P; Zheng CZ; Peng WB; Jiang RJ Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Feb; 24(2):113-5. PubMed ID: 12697111 [TBL] [Abstract][Full Text] [Related]
13. Cost benefit analysis of Japanese encephalitis vaccination program in Thailand. Siraprapasiri T; Sawaddiwudhipong W; Rojanasuphot S Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):143-8. PubMed ID: 9322297 [TBL] [Abstract][Full Text] [Related]
14. Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated). Kikukawa A; Gomi Y; Akechi M; Onishi T; Manabe S; Namazue J; Fuke I; Ishikawa T; Okuno Y; Ueda S Vaccine; 2012 Mar; 30(13):2329-35. PubMed ID: 22306856 [TBL] [Abstract][Full Text] [Related]
15. Flaviviruses and flavivirus vaccines. Heinz FX; Stiasny K Vaccine; 2012 Jun; 30(29):4301-6. PubMed ID: 22682286 [TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. Tauber E; Kollaritsch H; von Sonnenburg F; Lademann M; Jilma B; Firbas C; Jelinek T; Beckett C; Knobloch J; McBride WJ; Schuller E; Kaltenböck A; Sun W; Lyons A J Infect Dis; 2008 Aug; 198(4):493-9. PubMed ID: 18588481 [TBL] [Abstract][Full Text] [Related]
17. A special note on Japanese encephalitis vaccine. Lamabadusuriya SP Ceylon Med J; 1993 Sep; 38(3):103-4. PubMed ID: 7828224 [No Abstract] [Full Text] [Related]
18. [Observations on the reactions following vaccination of the inactivated Japanese encephalitis virus vaccine from tissue culture (author's transl)]. Zhonghua Yu Fang Yi Xue Za Zhi; 1981 Mar; 15(2):98-100. PubMed ID: 7307821 [No Abstract] [Full Text] [Related]
19. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547 [TBL] [Abstract][Full Text] [Related]